Výsledky vyhledávání - "Srihari Jaganathan"

Akademický článek

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry

Autor: Leslie R. Harrold, Heather J. Litman, Katherine C. Saunders, Kimberly J. Dandreo, Bernice Gershenson, Jeffrey D. Greenberg, Robert Low, Jeffrey Stark, Robert Suruki, Srihari Jaganathan, Joel M. Kremer, Mohamed Yassine

Publikováno v: Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)

Abstract Background Registry studies provide a valuable source of comparative safety data for tumor necrosis factor inhibitors (TNFi) used in rheumatoid arthritis (RA), but they are subject to channeling bias. Comparing safety outcomes without accoun

Externí odkaz: https://doaj.org/article/b0086cce10b7407b95e3ca6a90f94d2f

Zobrazit plný text záznamu

A combination-based forecasting method for the M4-competition

Autor: Srihari Jaganathan, P.K.S. Prakash

Publikováno v: International Journal of Forecasting. 36:98-104

Several researchers (Armstrong, 2001; Clemen, 1989; Makridakis and Winkler, 1983) have shown empirically that combination-based forecasting methods are very effective in real world settings. This paper discusses a combination-based forecasting approa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d362dd30908810e22865398eff0dab7f
https://doi.org/10.1016/j.ijforecast.2019.03.030

Zobrazit plný text záznamu

Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data

Autor: David A. Schwartz, Jay Gucky, Mohamed Yassine, Robert Low, Chakkarin Burudpakdee, Srihari Jaganathan, Douglas C. Wolf, Arpamas Seetasith, Edward Lee

Publikováno v: Patient Preference and Adherence.

Douglas C Wolf,1 Srihari Jaganathan,2 Chakkarin Burudpakdee,3 Arpamas Seetasith,3 Robert Low,2 Edward Lee,4 Jay Gucky,2 Mohamed Yassine,4 David A Schwartz5 1Atlanta Gastroenterology Associates, Atlanta, GA, 2UCB Pharma, Smyrna, GA, 3IQVIA, Fairfax, V

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9158482ef9c892c18e54f246818d63b
https://www.dovepress.com/adherence-rates-and-health-care-costs-in-crohns-disease-patients-recei-peer-reviewed-article-PPA

Zobrazit plný text záznamu

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry

Autor: Kimberly J. Dandreo, Robert Low, Joel M. Kremer, Bernice Gershenson, Leslie R. Harrold, Katherine C. Saunders, Mohamed Yassine, Robert Suruki, Jeff Greenberg, Jeffrey L Stark, Srihari Jaganathan, Heather J. Litman

Publikováno v: Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-11 (2018)
Arthritis Research & Therapy

Background Registry studies provide a valuable source of comparative safety data for tumor necrosis factor inhibitors (TNFi) used in rheumatoid arthritis (RA), but they are subject to channeling bias. Comparing safety outcomes without accounting for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::484cbb64bd2635d887ba04b179a7a06c
https://doi.org/10.1186/s13075-017-1496-5

Zobrazit plný text záznamu

Additional file 1: of One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry

Autor: Harrold, Leslie, Litman, Heather, Saunders, Katherine, Dandreo, Kimberly, Gershenson, Bernice, Greenberg, Jeffrey, Low, Robert, Stark, Jeffrey, Suruki, Robert, Srihari Jaganathan, Kremer, Joel, Yassine, Mohamed

Modified Charlson comorbidity index. Table S1. Other AEs of interest. (PDF 246Â kb)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::298520a4c3a69cfa3b44e5ddc0dfc1a3

Zobrazit plný text záznamu

Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn’s disease

Autor: Sunanda V. Kane, Angela V. Bedenbaugh, L.A. Palmer, David A. Schwartz, Srihari Jaganathan

Publikováno v: Current Medical Research and Opinion. 30:1821-1826

Corticosteroids are effective for inducing remission of Crohn's disease, but should not be used long term due to risk of adverse events. Benefits of immunosuppressants (e.g., azathioprine) and anti tumor necrosis factor (anti-TNF) agents include redu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f237b742bd5a82802f56518f668bc9e7
https://doi.org/10.1185/03007995.2014.928273

Zobrazit plný text záznamu

Fuzzy analytic hierarchy process based group decision support system to select and evaluate new manufacturing technologies

Autor: Srihari Jaganathan, Jinson J. Erinjeri, Jun-Ing Ker

Publikováno v: The International Journal of Advanced Manufacturing Technology. 32:1253-1262

Manufacturing organizations often make complex decisions in regards to investment in new manufacturing technologies (NMT). These NMT are assessed based on attributes such as flexibility, quality etc., which are hard to quantify. This fact calls upon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82cee215751d9aac2a57464fc3d7bebc
https://doi.org/10.1007/s00170-006-0446-1

Zobrazit plný text záznamu

Su1212 Incidence of Surgery and Associated Costs At 1 and 2 Years in Patients Newly Initiated to a Subcutaneous Anti-TNF for the Treatment of Crohn's Disease

Autor: David A. Schwartz, Sunni Jenkins, Sunanda V. Kane, Srihari Jaganathan

Publikováno v: Gastroenterology. 144:S-429

BACKGROUNDCrohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract. For patients with severe CD, uncontrolled inflammation can result in a high incidence of long-term complications, including surgery.[1] Anti-tumor necrosi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e536a06a1e2925385c46a080deefb8a
https://doi.org/10.1016/s0016-5085(13)61579-6

Zobrazit plný text záznamu

Su1210 Analysis of a US Patient Claims Database to Assess Appropriate Initial Dosing in Patients Newly Prescribed Certolizumab Pegol for Crohn's Disease

Autor: Srihari Jaganathan, Sunanda V. Kane, Fred M. Cox, David A. Schwartz, Sunni Jenkins

Publikováno v: Gastroenterology. 144:S-428

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::466df8688b0fb01df4baff5b12a1935a
https://doi.org/10.1016/s0016-5085(13)61577-2

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání